Urology
Volume 75, Issue 5 , Pages 1156-1161 , May 2010

Assessment of Patient-Reported Outcome of Patients With Lower Urinary Tract Symptoms Suggestive of Benign Prostatic Hyperplasia and Treated With Tamsulosin HCl in Korea

  • Hyuk Soo Chang

      Affiliations

    • Department of Urology, Dongsan Hospital, Keimyung University School of Medicine, Daegu, Korea
    • ,
  • Choal Hee Park

      Affiliations

    • Department of Urology, Dongsan Hospital, Keimyung University School of Medicine, Daegu, Korea
    • Corresponding Author InformationReprint requests: Choal Hee Park, M.D., 194 Dongsan-dong, Jung-gu, Dongsan Hospital, Department of Urology, Daegu, Korea
    • ,
  • Dae Kyung Kim

      Affiliations

    • Department of Urology, Eulji University Hospital, Daejeon, Korea
    • ,
  • Jong Kwan Park

      Affiliations

    • Department of Urology, Chonbuk National University Medical School, Jeonju, Korea
    • ,
  • Sung Joon Hong

      Affiliations

    • Department of Urology, Yonsei University College of Medicine, Seoul, Korea
    • ,
  • Byung Ha Chung

      Affiliations

    • Department of Urology, Yonsei University College of Medicine, Seoul, Korea
    • ,
  • Jeong Gu Lee

      Affiliations

    • Department of Urology, Korea University College of Medicine, Seoul, Korea
    • ,
  • Choung-Soo Kim

      Affiliations

    • Department of Urology, University of Ulsan College of Medicine, Ulsan, Korea
    • ,
  • Kyu-Sung Lee

      Affiliations

    • Department of Urology, Sungkyunkwan University School of Medicine, Seoul, Korea
    • ,
  • Joon Chul Kim

      Affiliations

    • Department of Urology, The Catholic University of Korea College of Medicine, Seoul, Korea

Received 23 July 2009 ,Accepted 5 September 2009.

References 

  1. Weiss JP, Blaivas JG, Anger JAT, et al. Development and validation of a new treatment outcome score for men with lutes. Neurourol Urodyn. 2004;23:88–93
  2. Rovner ES, Kreder K, Sussman DO, et al. Effect of tolterodine extended release with or without tamsulosin on measures of urgency and patient reported outcomes in men with lower urinary tract symptoms. J Urol. 2008;180:1034–1041
  3. Biggs GY, Ballert KN, Rosenblum N, et al. Patient-reported outcomes for tension-free vaginal tape-obturator in women treated with a previous anti-incontinence procedure. Int Urogynecol J Pelvic Floor Dysfunct. 2009;20:331–335
  4. De E, Pisters LL, Pettaway CA, et al. Salvage prostatectomy with bladder neck closure, continent catheterizable stoma, and bladder augmentation: feasibility and patient reported continence outcomes at 32 months. J Urol. 2007;177:2200–2204
  5. El-Azab AS, Abd-Elsayed AA, Imam HM. Patient reported and anatomical outcomes after surgery for pelvic organ prolapse. Neurourol Urodyn. 2009;28:219–224
  6. Cappelleri JC, Stecher VJ. An assessment of patient-reported outcomes for men with erectile dysfunction: Pfizer's perspective. Int J Impot Res. 2008;20:343–357
  7. Andersson K-E. Mode of action of α1-adrenoreceptor antagonists in the treatment of lower urinary tract symptoms. BJU Int. 2000;85:12–18
  8. Schwin DA. The role of α1-adrenergic receptor subtypes in lower urinary tract symptoms. BJU Int. 2001;88(suppl 2):27–34
  9. Abrams P, Schulman CC, Vaage S. Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic “obstruction” (symptomatic BPH). Br J Urol. 1995;76:325–336
  10. Chapple CR, Wyndaele JJ, Nordling J, et al. Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist (A meta-analysis of two randomized, placebo-controlled, multicenter studies in patients with benign prostatic obstruction (symptomatic BPH)). Eur Urol. 1996;29:155–167
  11. Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Urology. 1998;51:892–900
  12. Park CH, Chang HS, Oh BR, et al. Efficacy of low-dose tamsulosin on lower urinary tract symptoms suggestive of benign prostatic hyperplasia. Clin Drug Invest. 2004;24:41–47
  13. Li NC, Chen S, Yang XH, et al. Efficacy of low-dose tamsulosin in Chinese patients with symptomatic benign prostatic hyperplasia. Clin Drug Invest. 2003;23:781–787
  14. Rahardjo D, Soebadi DM, Sugandi S, et al. Efficacy and safety of tamsulosin hydrochloride compared to doxazosin in the treatment of Indonesian patients with lower urinary tract symptoms due to benign prostatic hyperplasia. Int J Urol. 2006;13:1405–1409
  15. Suzuki H, Yano M, Awa Y, et al. Clinical impact of tamsulosin on generic and symptom-specific quality of life for benign prostatic hyperplasia patients: using international prostate symptom score and Rand medical outcomes Study 36-item Health Survey. Int J Urol. 2006;13:1202–1206
  16. Yalla SV, Sullivan MP, Lecamwasam HS, et al. Correlation of American Urological Association symptom index with obstructive and nonobstructive prostatism. J Urol. 1995;153:674–679
  17. McConnell JD, Barry MJ, Bruskewitz RC, et al. Benign prostatic hyperplasia: diagnosis and treatment, clinical practice guideline No. 8. Rockville, MD: Department of Health and Human Services, Agency for Health Care Policy and Research, Public Health Service, US; 1994;Publication No. 94-0582
  18. Groutz A, Blaivas JG, Chaikin DC, et al. Noninvasive outcome measures for urinary incontinence: a multicenter study of voiding diaries and pad tests. J Urol. 2000;164:698–701
  19. Barry MJ, Fowler FJ, O'Leary MP, et al. AUA Measurement Committee The American Urological Association symptom index for benign prostatic hyperplasia. J Urol. 1992;148:1549–1557
  20. Blaivas JG, Chancellor M. Deciding on the right urodynamic equipment. In:  Blaivas J,  Chancellor M editor. Atlas of Urodynamics. Baltimore, MD: Williams and Wilkins; 1997;p. 19–37
  21. Michel MC, Mehlburger L, Bressel H-U, et al. Comparison of tamsulosin efficacy in subgroups of patients with lower urinary tract symptoms. Prostate Cancer Prostatic Dis. 1998;1:332–335
  22. Barry MJ, Williford WO, Chang Y, et al. Benign prostatic hyperplasia specific healthy status measures in clinical research: how much change in the American Urological Association symptom index and the benign prostatic hyperplasia impact index is perceptible to patients?. J Urol. 1995;154:1770–1774

 This study was supported by a grant from Astellas Pharmaceutical Co., Ltd.

PII: S0090-4295(09)02532-1

doi: 10.1016/j.urology.2009.09.010

Urology
Volume 75, Issue 5 , Pages 1156-1161 , May 2010

Article Tools